Manlio Fabio Márquez-Murillo , Juan Manuel Montero Echeverri , Wikler Bernal Torres , Noel Alberto Flórez Alarcón , Manuela Escalante , Estevão Lanna Figueiredo , Ricardo Enrique Larrea Gómez , Daniel Sierra-Lara , César Herrera , Julián Lugo , Liliana Patricia Cárdenas Aldaz , Paula Silva , William Millán Orozco , Yorlany Rodas-Cortez , Andrea Valencia , Juan Esteban Gómez-Mesa
{"title":"拉丁美洲心房颤动和严重 COVID-19 的心血管后果：CARDIO COVID 登记 19-20","authors":"Manlio Fabio Márquez-Murillo , Juan Manuel Montero Echeverri , Wikler Bernal Torres , Noel Alberto Flórez Alarcón , Manuela Escalante , Estevão Lanna Figueiredo , Ricardo Enrique Larrea Gómez , Daniel Sierra-Lara , César Herrera , Julián Lugo , Liliana Patricia Cárdenas Aldaz , Paula Silva , William Millán Orozco , Yorlany Rodas-Cortez , Andrea Valencia , Juan Esteban Gómez-Mesa","doi":"10.1016/j.rccl.2023.09.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction y objectives</h3><p>Cardiovascular complications of coronavirus disease 2019 (COVID-19) include various arrhythmias, particularly atrial fibrillation (AF), which has been linked as a risk factor for adverse events, impacting mortality during active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No studies have investigated this in the Latin American population; thus, we evaluated the impact of a history of AF on intrahospital morbidity and mortality in COVID-19 patients.</p></div><div><h3>Methods</h3><p>A multicenter, retrospective observational analysis was conducted based on the Latin American CARDIO COVID 19-20registry, including COVID-19 patients from 14 Latin American countries.</p></div><div><h3>Results</h3><p>Of the 3260 SARS-CoV-2-positive patients, 3.5% had a history of AF. This group had a higher prevalence of hypertension (70.4% vs 48.2%; <em>P</em><.001), heart failure (43.4% vs 4.2%; <em>P</em><.001), and dyslipidemia (30.4% vs 13.2%; <em>P</em><.001) than those without AF. Additionally, they had higher values of troponin I (0.03 vs 0.01; <em>P</em><.001) and NT-proBNP (3045 vs 341.1; <em>P</em> <<!--> <!-->.001). Cardiovascular complications, such as decompensated heart failure (39.1% vs 7.4%; <em>P</em><.001) and arrhythmias (40.9% vs 7.9%; <em>P</em><.001), and in-hospital mortality were more prevalent in the AF group (40.0% vs 25.5%; <em>P</em><.001).</p></div><div><h3>Conclusions</h3><p>In Latin America, COVID-19 patients with a history of AF had higher values of cardiac damage biomarkers, more cardiovascular complications, and higher in-hospital mortality.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 1","pages":"Pages 23-34"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Desenlaces cardiovasculares en fibrilación auricular y COVID-19 grave en Latinoamérica: registro CARDIO COVID 19-20\",\"authors\":\"Manlio Fabio Márquez-Murillo , Juan Manuel Montero Echeverri , Wikler Bernal Torres , Noel Alberto Flórez Alarcón , Manuela Escalante , Estevão Lanna Figueiredo , Ricardo Enrique Larrea Gómez , Daniel Sierra-Lara , César Herrera , Julián Lugo , Liliana Patricia Cárdenas Aldaz , Paula Silva , William Millán Orozco , Yorlany Rodas-Cortez , Andrea Valencia , Juan Esteban Gómez-Mesa\",\"doi\":\"10.1016/j.rccl.2023.09.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction y objectives</h3><p>Cardiovascular complications of coronavirus disease 2019 (COVID-19) include various arrhythmias, particularly atrial fibrillation (AF), which has been linked as a risk factor for adverse events, impacting mortality during active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No studies have investigated this in the Latin American population; thus, we evaluated the impact of a history of AF on intrahospital morbidity and mortality in COVID-19 patients.</p></div><div><h3>Methods</h3><p>A multicenter, retrospective observational analysis was conducted based on the Latin American CARDIO COVID 19-20registry, including COVID-19 patients from 14 Latin American countries.</p></div><div><h3>Results</h3><p>Of the 3260 SARS-CoV-2-positive patients, 3.5% had a history of AF. This group had a higher prevalence of hypertension (70.4% vs 48.2%; <em>P</em><.001), heart failure (43.4% vs 4.2%; <em>P</em><.001), and dyslipidemia (30.4% vs 13.2%; <em>P</em><.001) than those without AF. Additionally, they had higher values of troponin I (0.03 vs 0.01; <em>P</em><.001) and NT-proBNP (3045 vs 341.1; <em>P</em> <<!--> <!-->.001). Cardiovascular complications, such as decompensated heart failure (39.1% vs 7.4%; <em>P</em><.001) and arrhythmias (40.9% vs 7.9%; <em>P</em><.001), and in-hospital mortality were more prevalent in the AF group (40.0% vs 25.5%; <em>P</em><.001).</p></div><div><h3>Conclusions</h3><p>In Latin America, COVID-19 patients with a history of AF had higher values of cardiac damage biomarkers, more cardiovascular complications, and higher in-hospital mortality.</p></div>\",\"PeriodicalId\":36870,\"journal\":{\"name\":\"REC: CardioClinics\",\"volume\":\"59 1\",\"pages\":\"Pages 23-34\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"REC: CardioClinics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2605153223002856\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"REC: CardioClinics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2605153223002856","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
2019冠状病毒病(COVID-19)的心血管并发症包括各种心律失常，特别是房颤(af)。它被认为是不良事件发生的危险因素，影响严重急性呼吸道综合征2型(SARS-CoV-2)活动性冠状病毒感染期间的死亡率。在拉丁美洲人群中没有这方面的研究，因此我们评估了FA病史对COVID-19患者住院发病率和死亡率的影响。基于拉丁美洲心血管疾病和COVID-19登记处(CARDIO COVID- 19-20)的多中心回顾性观察分析，涵盖了14个拉丁美洲国家的COVID-19患者。本研究的目的是评估一项研究的结果，该研究的目的是评估一项研究的结果。在组中，高血压患病率较高(70.4比48.2%;p < 0.001)，心力衰竭(43.4 vs 4.2%;p < 0.001)和血脂异常(30.4 vs 13.2%;p < 0.001)与非房颤患者相比。此外，肌钙蛋白I值较高(0.03比0.01;p < 0.001)和NT-proBNP (3.045 vs 341.1;p < 0.001)。心血管并发症，如失代偿性心力衰竭(39.1 vs . 7.4%;p < 0.001)和心律失常(40.9 vs . 7.9%;p < 0.001)和住院死亡率在FA组更为普遍(40.0 vs 25.5%;p < 0.001)。在拉丁美洲，有af病史的SARS-CoV-2患者心脏损伤生物标志物值更高，心血管并发症更多，住院死亡率更高。2019冠状病毒病(COVID-19)的心血管并发症包括各种心律失常，特别是房颤(fa)，这与严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2)活动性感染期间影响死亡率的不良事件风险因素有关。没有研究在拉丁美洲人口中对此进行调查;因此，我们评估了fa史对COVID-19患者住院发病率和死亡率的影响。基于拉丁美洲心血管COVID-19 -20记录，包括来自14个拉丁美洲国家的COVID-19患者，进行了多中心回顾性观察分析。在3260例sars - cov -2阳性患者中，3.5%有sca病史，高血压患病率较高(70.4% vs 48.2%;P<.001)，心脏衰竭(43.4% vs 4.2%;P<.001)和血脂异常(30.4% vs 13.2%;此外，它们的肌钙蛋白I值较高(0.03 vs 0.01;P<.001)和NT-proBNP (3045 vs 341.1;P < .001)。心血管并发症，如失代偿性心力衰竭(39.1% vs 7.4%;P<.001)和心律失常(40.9% vs . 7.9%;P<.001)，住院死亡率在AF组更为普遍(40.0% vs 25.5%;P < 001)。在拉丁美洲，有fa史的COVID-19患者心脏损伤生物标志物值较高，心血管并发症较多，住院死亡率较高。
Desenlaces cardiovasculares en fibrilación auricular y COVID-19 grave en Latinoamérica: registro CARDIO COVID 19-20
Introduction y objectives
Cardiovascular complications of coronavirus disease 2019 (COVID-19) include various arrhythmias, particularly atrial fibrillation (AF), which has been linked as a risk factor for adverse events, impacting mortality during active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No studies have investigated this in the Latin American population; thus, we evaluated the impact of a history of AF on intrahospital morbidity and mortality in COVID-19 patients.
Methods
A multicenter, retrospective observational analysis was conducted based on the Latin American CARDIO COVID 19-20registry, including COVID-19 patients from 14 Latin American countries.
Results
Of the 3260 SARS-CoV-2-positive patients, 3.5% had a history of AF. This group had a higher prevalence of hypertension (70.4% vs 48.2%; P<.001), heart failure (43.4% vs 4.2%; P<.001), and dyslipidemia (30.4% vs 13.2%; P<.001) than those without AF. Additionally, they had higher values of troponin I (0.03 vs 0.01; P<.001) and NT-proBNP (3045 vs 341.1; P < .001). Cardiovascular complications, such as decompensated heart failure (39.1% vs 7.4%; P<.001) and arrhythmias (40.9% vs 7.9%; P<.001), and in-hospital mortality were more prevalent in the AF group (40.0% vs 25.5%; P<.001).
Conclusions
In Latin America, COVID-19 patients with a history of AF had higher values of cardiac damage biomarkers, more cardiovascular complications, and higher in-hospital mortality.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
